

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Highly Specialised Technologies Evaluation

OTL-200 for treating metachromatic leukodystrophy ID1666

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Orchard Therapeutics (OTL-200) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Alex, The Leukodystrophy Charity • ArchAngel MLD Trust • Brain and Spine Foundation • Brain Charity • Find a Cure • Genetic Alliance UK • Metabolic Support UK • MLD Support Association UK • MPS Society • Muslim Council of Britain • National Children's Bureau • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Genetic Nurses and Counsellors • British Geriatrics Society • British Neuropathological Society • British Paediatric Neurology Association • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Human Genetics • British Society for Haematology • Institute for Neurology • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Cochrane Cystic Fibrosis and Genetic Disorders Group • Genomics England

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Genetic Testing Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Birmingham Children's Hospital NHS Foundation Trust; • Cambridge University Hospitals NHS Foundation Trust; • Department of Health and Social Care • Great Ormond Street Hospital for Children NHS Foundation Trust; • Manchester University NHS Foundation Trust; • NHS England • Royal Free London NHS Foundation Trust; • Salford Royal NHS Foundation Trust; • University College London Hospital NHS Foundation Trust; • University Hospitals Birmingham NHS Foundation Trust 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.